Swiss pharma giant Roche (ROG: SIX) has entered into a new partnership with USA-based Alnylam Pharmaceuticals (Nasdaq: ALNY) to develop and commercialize zilebesiran, the latter’s investigational RNAi therapeutic currently in Phase II for the treatment of hypertension.
In July 2007, Roche and Alnylam entered into a major alliance in which Roche obtained a non-exclusive license to Alnylam's technology platform for developing RNAi (RNA interference) therapeutics.
According to the companies, based on the positive Phase I data, zilebesiran could be a best-in-disease treatment and provide transformational benefit, especially for patients with hypertension at high cardiovascular risk. It also has the potential of improved adherence and compliance to treatment due to the possible biannual subcutaneous dosing regime. In addition, zilebesiran could provide patient benefit in additional cardiovascular indications with high unmet medical need.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze